Fibroblast growth factor (FGF)-21 signals through both FGF receptor-1 and 2
5
Citation
22
Reference
10
Related Paper
Citation Trend
Keywords:
3T3 cells
FGF21
Fibroblast growth factor 2 (FGF2) is a family of isoforms with potential both as therapeutic molecules, as well as endogenous targets for pharmacological modulation in cardiac ischemia. Our laboratory has previously demonstrated that the secreted low moledular weight (LMW) FGF2 isoform protects the heart against myocardial dysfunction induced by ischemia‐reperfusion (I/R) injury by activating the FGF receptor 1 (FGFR1), while the mechanisms by which the high molecular weight (HMW) FGF2 isoforms produce the opposing and detrimental effects on cardiac function following I/R are less clear. The purpose of this study was to examine whether FGFR1 activation is necessary for the effects of HMW FGF2. Using an isolated work‐perfoming heart model, mice overexpressing the 24kDa isoform of FGF2 were subjected to global low‐flow ischemia in the presence of an inhibitor to FGFR1. The blockade of FGFR1 resulted in higher post‐ischemic contractility in transgenic hearts (p<0.05). We also found differences in the activation of kinases downstream from FGFR1, including protein kinase C (PKC) and mitogen activated protein kinases (MAPKs), indicating that HMW FGF2 alters the targets of FGFR1 signaling cascades. These findings indicate that HMW FGF2 mediates its effects by modulating FGFR1 signaling, to induce post‐ischemic myocardial dysfunction. Research supported by NIH grant NIH/NHLBI RO1 HL075633
Contractility
Cite
Citations (0)
Fibroblast growth factors (FGF) are multifunctional, heparin binding polypeptides that share structural similarity, but differ in their target cell specificity and expression pattern. Here we describe the cloning and expression of the mouse homologue of FGF9, and the use of a panel of soluble FGF receptors and genetically engineered cells to study its receptor binding specificity. FGF9 is found to bind with high affinity (kd: 0.25 nM) to FGFR3, for which a specific ligand has not yet been identified. FGF9 can also bind, albeit with a lower affinity, to FGFR2 but does not bind FGFR1 or FGFR4. There is no significant binding to either FGFR3 or FGFR2, expressed either as soluble receptors or in heparan sulfate deficient cells, in the absence of heparin. Moreover, receptor binding of FGF9 requires heparin in a manner specific to the receptor type. In conclusion FGF9 presents a unique case of ligand-receptor specificity and fulfills the criteria as a high affinity, heparin-dependent ligand for FGFR3.
FGF9
Cite
Citations (111)
FGF21
FGF1
Cite
Citations (0)
FGF21
Carbohydrate Metabolism
Cite
Citations (1)
ABSTRACT The Fgf8 gene is expressed in developing limb and craniofacial structures, regions known to be important for growth and patterning of the mouse embryo. Although Fgf8 is alternatively spliced to generate at least 7 secreted isoforms that differ only at their mature amino terminus, the biological significance of these multiple isoforms is not known. In this report, we demonstrate that multiple FGF-8 isoforms are present at sites of Fgf8 expression during mouse development. To address the possibility that the FGF-8 isoforms might interact with different fibroblast growth factor receptors, we prepared recombinant FGF-8 protein isoforms. We examined the ability of these proteins to activate alternatively spliced forms of fibroblast growth factor receptors 1–3, and fibroblast growth factor receptor 4. Recombinant FGF-8b and FGF-8c activate the ‘c’ splice form of FGFR3, and FGFR4, while FGF-8b also efficiently activates ‘c’ splice form of FGFR2. No activity could be detected for recombinant or cell expressed FGF-8a. Furthermore, none of the isoforms tested interact efficiently with ‘b’ splice forms of FGFR1-3, or the ‘c’ splice form of FGFR1. These results indicate that the FGF-8b and FGF8c isoforms, produced by ectodermally derived epithelial cells, interact with mesenchymally expressed fibroblast growth factor receptors. FGF-8b and FGF-8c may therefore provide a mitogenic signal to the underlying mesenchyme during limb and craniofacial development.
FGF8
Limb development
Cite
Citations (223)
Internalization
Cite
Citations (118)
The vertebrate fibroblast growth factor receptor 1 (FGFR1) is alternatively spliced generating multiple splice variants that are differentially expressed during embryo development and in the adult body. The restricted expression patterns of FGFR1 isoforms, together with differential expression and binding of specific ligands, leads to activation of common FGFR1 signal transduction pathways, but may result in distinctively different biological responses as a result of differences in cellular context. FGFR1 isoforms are also present in the nucleus in complex with various fibroblast growth factors where they function to regulate transcription of target genes.
Cite
Citations (101)
Fibroblast growth factor (FGF) 21, a structural relative of FGF23 that regulates phosphate homeostasis, is a regulator of insulin-independent glucose transport in adipocytes and plays a role in the regulation of body weight. It also regulates ketogenesis and adaptive responses to starvation. We report that in a reconstituted receptor activation assay system using BaF3 cells, which do not endogenously express any type of FGF receptor (FGFR) or heparan sulfate proteoglycan, FGF21 alone does not activate FGFRs and that betaKlotho is required for FGF21 to activate two specific FGFR subtypes: FGFR1c and FGFR3c. Coexpression of betaKlotho and FGFR1c on BaF3 cells enabled FGF21, but not FGF23, to activate receptor signaling. Conversely, coexpression of FGFR1c and Klotho, a protein related to betaKlotho, enabled FGF23 but not FGF21 to activate receptor signaling, indicating that expression of betaKlotho/Klotho confers target cell specificity on FGF21/FGF23. In all of these cases, heparin enhanced the activation but was not essential. In 3T3-L1 adipocytes, up-regulation of glucose transporter (GLUT) expression by FGF21 was associated with expression of betaKlotho, which was absent in undifferentiated 3T3-L1 fibroblasts. It is thus suggested that betaKlotho expression is a crucial determinant of the FGF21 specificity of the target cells upon which it acts in an endocrine fashion.
FGF21
FGF8
Klotho
FGF1
Cite
Citations (315)
3T3 cells
FGF21
Cite
Citations (5)